drugset
Drugs / TCR redirected T cells
last change Jun 2024 re-read 3 minutes ago

TCR redirected T cells

also known as HBV-TCR-T · HBV-TCR-T cells

Cell therapy

Developed for
hepatocellular carcinoma
Investigated by
Beijing 302 Hospital · Lion TCR Pte. Ltd.

Trials 1

today NCT03899415 · Ph 1
2020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT03899415 Apr 2019 → Jun 2022 hepatocellular carcinoma Beijing 302 Hospital Unknown No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as TCR redirected T cells ClinicalTrials.gov intervention name — accepted as the source's own label NCT03899415 ↗
Known as HBV-TCR-T “Immunotherapy with hepatitis B virus (HBV)-specific TCR redirected T (HBV-TCR-T) cells in HBV-related hepatocellular carcinoma (HBV-HCC) patients after liver transplantation...” PMID 34850325 ↗ Nov 2021
Known as HBV-TCR-T cells “Immunotherapy with hepatitis B virus (HBV)-specific TCR redirected T (HBV-TCR-T) cells in HBV-related hepatocellular carcinoma (HBV-HCC) patients after liver transplantation...” PMID 34850325 ↗ Nov 2021
Modality Cell therapy “adoptively transferred short-lived autologous T cells expressing HBV-specific TCR” PMID 34850325 ↗ Nov 2021
Route Intravenous “TCR redirected T cells by IV infusion” NCT03899415 ↗